美托洛尔联合厄贝沙坦治疗缺血性心肌病心衰竭

目的探讨美托洛尔联合厄贝沙坦治疗缺血性心肌病心衰竭的临床疗效。方法 78例缺血性心肌病心衰竭患者作为研究对象,随机分为观察组(40例)和常规治疗组(38例),2组均常规给予强心、利尿、补钾及扩血管等综合治疗,而观察组在常规治疗组的基础上,美托洛尔12.5～50 mg,2次/d,厄贝沙坦80～150 mg,1次/d。2组疗程平均治疗16～24周后,观察治疗前后心率(HR)、血压(BP)、左室射血分数(LVEF)、左心室舒张末内径(LVEDD)、左室收缩末期内径(LVESD)等指标的变化。结果经治疗后,两组患者的心功能均明显改善,观察组与常规治疗组的临床总有效率分别为95.00%和76.32%。且观察组的患者心率减慢、血压下降、LVEF、LVEDD、LVESD显著改善,且优于对照组(P0.05)。结论美托洛尔联合厄贝沙坦治疗缺血性心肌病心衰竭,可显著改善患者的心功能,逆转心室重构,可显著提高临床疗效。

Analysis of the clinical efficacy of metoprolol and irbesartan treatment on ischemic cardiomyopathy heart failure

Objective To investigate the clinical efficacy of metoprolol and irbesartan treatment on ischemic cardiomyopathy heart failure.Methods All 78 cases of ischemic cardiomyopathy patients with heart failure as objects of study were randomly divided into two groups: the observation group(40 cases) and the conventional therapy group(38 cases).The two groups were given conventional cardiac,diuretic,potassium,and vasodilative treatment.Based on the conventional therapy group,the observation group was administered metoprolol 12.5 ~ 50mg,bid,and irbesartan 80 ~150 mg.Treatment lasted an average of 16 to 24 weeks.Heart rate(HR),blood pressure(BP),left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD) and other indicators’ change before and after treatment were observed.Results After the treatment,heart function of the two groups’ patients was significantly improved.The total clinical efficiency of the observation group and the conventional therapy group was 95% and 76.32%,respectively.And heart rate,blood pressure,LVEF,LVEDD,and LVESD of the observation group were significantly improved,and better than those of the control group(P<0.05).Conclusion Metoprolol and irbesartan treatment of ischemic cardiomyopathy with heart failure can significantly improve cardiac function and reversal of ventricular remodeling,which can significantly improve clinical outcomes.